Sending Office: Honorable Rosa L. DeLauro
Responsibility in Drug Adverting Act
3-Year Moratorium on Direct-to-Consumer Drug Advertising
Cosponsors: Reps. Khanna and Grijalva
In the coming days, I will reintroduce the Responsibility in Drug Advertising Act, a bill that I have been working on since 2005. This legislation would establish a moratorium on direct-to-consumer advertising for the first three years following
a drug’s approval.
Before the mid-1980s, drug companies only provided information about their products to doctors or pharmacists, who would relay information to their patients when appropriate. But during the 1980s, companies started to market their drugs directly to consumers
through ads. To date, federal law does not require the FDA to approve advertisements before they are released to the public. This practice has the potential to mislead consumers, which can be incredibly dangerous when it comes to people’s health.
The United States and New Zealand are the only two countries that even allow direct to consumer drug advertising. In 2007, the World Health Organization (WHO) made a strong recommendation against direct to consumer drug advertising, calling it, “a significant
risk of exposing more patients to the adverse effects of new drugs.” A by Dartmouth College and the University of Wisconsin-Madison found that nearly 60 percent of prescription drug advertisements were misleading or false. This puts consumers—our friends,
our families, our children, at risk.
Moreover, most of the prescription drugs advertised are more expensive, newer, and potentially riskier. Even though there are usually generic versions available, they do not generally get advertised.
For more information on this legislation, please contact Caitlin Peruccio (email@example.com) of my staff. The deadline to join as an original cosponsor is
COB, Monday, July 8th.
ROSA L. DeLAURO
Member of Congress
e-Dear Colleague version 2.0